FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology. A conjugate of the receptor-binding domain (RBD) protein of the surface glycoprotein S of the SARS-CoV-2 virus, 308V-542N, is described for obtaining a vaccine complex against the coronavirus infection COVID-19, developed in CHO cells, having a length of 244 a.a., molecular weight of 35 kDa, the amino acid sequence of SEQ ID N 2 associated with the polymer polyglucin-spermidine (PGS) at a calculated ratio of RBD protein molecules and PGS molecules - 1:1. Also described is a vaccine complex against coronavirus infection COVID-19 in the form of nanoparticles that induce the formation of T-cell immunity and SARS-CoV-specific antibodies with virus-neutralizing activity, and consisting of polyglucin-spermidine-protein RBD conjugate molecules according to claim 1 and plasmid molecules pVAX-RBD DNA, with each nanoparticle having a size of at least 50 nanometers, contains a core consisting of pVAX-RBD plasmid DNA molecules and a polyglucin-spermidine-protein RBD conjugate layer located around the core, retained due to ionic interaction between the negatively charged core and the positively charged core. charged spermidine.
EFFECT: creation of a simpler immunogenic construct, which, when administered intramuscularly, is capable of inducing a high level of antibodies with virus-neutralizing activity, as well as providing a virus-specific T-cell response.
3 cl, 16 dwg, 1 tbl, 6 ex
